PCOS and Psoriasis: A Risk That Runs in Both Directions

Why do PCOS and psoriasis show up together?

Women with PCOS carry roughly double the risk of later being diagnosed with psoriasis, and the relationship runs in the other direction too: women who already have psoriasis are diagnosed with PCOS at close to seven times the rate of the general population. Neither number means one condition causes the other — both point toward a shared metabolic and inflammatory substrate that produces both conditions independently, in the same person, more often than chance alone would predict.

The clearest evidence for the PCOS-to-psoriasis direction comes from a Taiwanese national health-insurance cohort of 4,707 women with PCOS matched to 18,828 controls without PCOS or psoriasis, followed from 2000 to 2012. Psoriasis was diagnosed at 0.70 per 1,000 person-years in the PCOS group versus 0.34 per 1,000 person-years in matched controls — a hazard ratio of 2.07 (95% CI 1.25–3.43). The reverse direction is stronger in absolute terms: a cross-sectional study of 51 women with psoriasis and 102 age- and BMI-matched controls found PCOS present in 47.05% of the psoriasis group versus 11.76% of controls — an odds ratio of 6.66 (95% CI 2.95–15.07). Both are observational designs, a cohort study and a cross-sectional study, which can show that two conditions cluster together far more than chance predicts but cannot show that either one causes the other.

Note: in May 2026, PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, by a global consensus of more than 50 organisations. The metabolic mechanism connecting it to psoriasis did not change — only the label did. This article uses PCOS, since that is still the term most readers search.

Does psoriasis severity actually track with metabolic risk?

Psoriasis severity moves in step with metabolic risk, not just its presence or absence. A pooled analysis of 12 observational studies covering 1.4 million people, including 41,853 with psoriasis, found an overall odds ratio of 2.26 (95% CI 1.70–3.01) for metabolic syndrome in psoriasis compared with the general population, and a dose-response relationship in which more severe psoriasis carried higher odds of metabolic syndrome than milder disease.

That severity link holds even below the threshold for a formal metabolic syndrome diagnosis. In a case-control study of 128 psoriasis patients split by whether they met metabolic syndrome criteria, Psoriasis Area and Severity Index (PASI) score correlated with HOMA-IR — a standard marker of insulin resistance — even after adjusting for BMI, and the correlation held (p < 0.001) among patients who did not meet metabolic syndrome criteria at all. Psoriasis severity predicted insulin resistance on its own, independent of whether the broader metabolic syndrome label applied.

Does having PCOS change how severe your psoriasis is likely to be?

For readers with both conditions, which PCOS phenotype is present appears to matter more than having PCOS as a single yes/no category. A cross-sectional study of 150 psoriasis patients — 94 with PCOS split into the four Rotterdam phenotypes, and 56 age- and BMI-matched psoriasis-only controls found severity running in different directions depending on which phenotype was present. Women with the complete phenotype — excess androgens, irregular cycles, and polycystic ovaries all three — had close to five times the odds of a high PASI score (≥10) compared with controls (OR 4.71, 95% CI 1.59–13.95). Women with irregular cycles and polycystic ovaries but no measurable androgen excess had markedly higher odds of moderate-to-severe disease by physician assessment (OR 26.79, 95% CI 3.40–211.02) — a wide interval that reflects a small subgroup and is worth reading as a strong signal to replicate, not a precise number. The ovulatory phenotype — androgen excess and polycystic ovaries, but regular cycles — ran the opposite way, with lower odds of severe disease than controls (OR 0.06, 95% CI 0.01–0.51).

The pattern that repeats across the two phenotypes with worse psoriasis is irregular or absent ovulation, not androgen excess by itself — the ovulatory phenotype had androgen excess without the cycle disruption, and it was the one phenotype with milder disease. That is a single study of 150 women and needs replication before it changes how psoriasis is managed, but it is a concrete, checkable pattern rather than a vague “PCOS is linked to psoriasis” statement.

What does the shared risk mean for screening?

A psoriasis diagnosis is a reasonable prompt to ask about PCOS screening, and a PCOS diagnosis is a reasonable prompt to mention any skin changes to a dermatologist, because both conditions point toward the same underlying metabolic picture worth checking either way. The 2023 international evidence-based guideline for PCOS already recommends assessing cardiometabolic risk — fasting glucose or an oral glucose tolerance test, a lipid panel, and blood pressure — as part of routine PCOS care (Teede et al., 2023); someone with psoriasis and any PCOS symptoms (irregular cycles, acne, excess hair growth) has a specific reason to ask for that panel rather than waiting for it to come up. Chronic low-grade inflammation, measured by CRP, is elevated in PCOS independent of body weight, and the same inflammatory activity is a recognised driver of psoriasis flares — one more reason the two conditions are worth screening for together rather than treating a diagnosis of either one as the end of the conversation. The insulin resistance underlying both the metabolic syndrome numbers above and PCOS itself is also directly testable with a fasting insulin and glucose panel, not something that has to be inferred from symptoms alone.

Does treating one condition actually improve the other?

The evidence here is thin, and it is worth saying so plainly rather than implying a treatment crossover that has not been demonstrated. A 2023 meta-analysis pooling three randomized controlled trials of metformin — an insulin-sensitising drug used first-line in PCOS — added to standard psoriasis treatment found a large improvement in the odds of a 75% reduction in psoriasis severity (OR 22.02, 95% CI 2.12–228.49), alongside reductions in fasting glucose, triglycerides, total cholesterol and LDL. That headline number looks dramatic, but a 95% confidence interval spanning from just above 2 to nearly 230 reflects only three small trials, and a result that fragile needs to be replicated in larger, independently run trials before it supports a treatment recommendation. No comparably designed trial has tested whether treating psoriasis first improves PCOS’s reproductive or metabolic symptoms. Until that evidence exists, the honest read is that both conditions share a metabolic root worth treating on its own terms — not that fixing one is a proven route to fixing the other.

What about psoriasis treatments during pregnancy or when trying to conceive?

Methotrexate, one of the most commonly used systemic treatments for moderate-to-severe psoriasis, is teratogenic, and this matters directly on a site where many readers are trying to conceive. A detailed teratogen review describes a recognisable pattern — growth deficiency, skull and facial bone abnormalities, and limb defects — most consistently linked to exposure between six and eight weeks after conception at doses of 10 mg per week or higher; case reports of much earlier exposure, before six weeks, describe a distinct pattern that may include heart defects. This is not a rare, worst-case scenario limited to high-dose cancer treatment — it is described at the dose ranges used in dermatology.

Because of this, methotrexate is one of a small group of drugs that professional guidelines say must be stopped before a pregnancy is attempted, not simply avoided once pregnancy is confirmed. A European task force representing 15 professional societies concluded that methotrexate “requires discontinuation before conception due to proven teratogenicity,” alongside two other drugs in the same category. In practice, that means reliable contraception throughout treatment and a clinician-defined drug-free interval completed before actively trying to conceive — the specific length of that interval, and how it is timed against your particular dose and treatment history, is a decision for the prescribing dermatologist and, ideally, a fertility clinician together, not a fixed number to apply on your own.

Other systemic psoriasis treatments carry their own pregnancy-specific precautions — this article covers methotrexate specifically because it is the one most readers are likely to encounter, not because it is the only one to ask about. Anyone on a systemic psoriasis medication who is trying to conceive, or could become pregnant, should confirm the specific drug’s pregnancy guidance with the prescribing clinician rather than assuming a treatment is fine because it has worked well so far.

What this association does not mean for you

An elevated odds ratio describes a population, not a prediction for one person. In the study with the strongest reported prevalence, PCOS was still absent in the majority of women with psoriasis — 47.05% is well under half. A shared risk factor is a reason to ask a clinician about screening, not a reason to assume a second diagnosis is inevitable, and it is not evidence that either condition was caused by something you did. The observational studies behind every number on this page also cannot say whether the biology runs from insulin resistance outward to both conditions, from chronic inflammation outward to both, or through some other shared pathway entirely — that mechanistic question is still open, which is exactly why the mitochondrial-dysfunction finding above is described as a plausible thread rather than an answer.

Your next step

If you have psoriasis and any signs of PCOS — irregular cycles, new acne, or excess hair growth — ask for the standard PCOS metabolic panel (fasting glucose or OGTT, lipids, blood pressure) rather than waiting for a formal PCOS diagnosis first. If you have PCOS and psoriasis develops or worsens, mention the PCOS diagnosis to your dermatologist, since it may be a relevant piece of the metabolic picture they are already tracking. For the wider set of skin changes PCOS can cause on its own, see the full symptoms guide.